ABOUT USBringing our nanoparticles to clinic has the potential to revolutionize how we approach personalized medicine, providing lifesaving immunotherapeutics to thousands of patients.
Aptabridge Therapeutics is creating a next generation drug design platform to leverage DNA nanoparticles for immunotherapy. We develop highly stable multi specific molecules with the aim to treat multifaceted, complex diseases by engaging two disease targets with one molecule.
By employing DNA nanoparticles instead of antibodies for immunotherapy, we will overcome challenges faced by bispecific antibodies with a product that promises to be safer, lower cost, and easier to manufacture. We are also employing a modular design strategy that allows us to reliably mix and match binding modules on our nanoparticles. This allows us to take working immune targeting modules and swap out different disease targeting modules to treat a wide range of diseases, making this platform highly versatile and scalable.
Our vision for this platform is to produce an AI-augmented system that can be used directly in the clinic to take patient tissue, analyze for unique biomarkers, then synthesize a therapeutic molecule all in one device.
DNA nanoparticles exhibit several key advantages
Fast
selection
selection
Shorter and cheaper
production time
production time
High quality
reproductibility
reproductibility
High
flexibility
flexibility
Thermal
stability
stability
Our technology combines the best of biologics and small molecules
Aptabridge Team
As a team, we are uniquely equipped with expertise across Science, Business and Medicine.
COFOUNDERJulie Clauss
- MS in Chem Engineering and MIT SFMBA
- 17+ years as Global Business Executive
CEO/CSO and COFOUNDER W. Taylor Cottle
- PhD in Biochemistry and Biophysics
- 15+ years molecular biology research experience
COO and COFOUNDERSebastien Vallee
- Pharm D and PhD in Biochemistry
- 10+ years of experience in R&D in the Bio-Pharma industry